{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:33:35Z","timestamp":1791851615451,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA46592"],"award-info":[{"award-number":["CA46592"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA099985"],"award-info":[{"award-number":["CA099985"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA123088"],"award-info":[{"award-number":["CA123088"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA152470"],"award-info":[{"award-number":["CA152470"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA193136"],"award-info":[{"award-number":["CA193136"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA217648"],"award-info":[{"award-number":["CA217648"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["I01BX005267"],"award-info":[{"award-number":["I01BX005267"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["L863220"],"award-info":[{"award-number":["L863220"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["MRA689853"],"award-info":[{"award-number":["MRA689853"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["VA150CU000182"],"award-info":[{"award-number":["VA150CU000182"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"Rogel Cancer Center, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ccell.2022.12.008","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T10:33:58Z","timestamp":1673519638000},"page":"304-322.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":152,"title":["Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy"],"prefix":"10.1016","volume":"41","author":[{"given":"Gaopeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Eun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Kryczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamya","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Fecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishal","family":"Mendiratta-Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica J.","family":"Waninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alangoya","family":"Tezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Ramnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Cieslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2022.12.008_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","article-title":"Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm","volume":"17","author":"Robert","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib4","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib5","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib7","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ccell.2022.12.008_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.12.008_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In\u00a0vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-20-1571","article-title":"Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation","volume":"11","author":"Du","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2022.12.008_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib15","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib16","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41556-020-0495-y","article-title":"Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-gamma signalling","volume":"22","author":"Singh","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2022.12.008_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/beta-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib24","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.ccell.2022.12.008_bib26","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib27","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2022.12.008_bib28","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2022.12.008_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ccell.2022.12.008_bib32","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","article-title":"Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria","volume":"26","author":"Matos","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib34","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/annonc\/mdz123","article-title":"Hyperprogressive disease during PD-1\/PD-L1 blockade in patients with non-small-cell lung cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib36","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jtho.2019.05.033","article-title":"Comprehensive clinical and genetic characterization of hyperprogression based on volumetry in advanced non-small cell lung cancer treated with immune checkpoint inhibitor","volume":"14","author":"Kim","year":"2019","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lungcan.2019.01.010","article-title":"Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: an early report","volume":"129","author":"Tunali","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/CAD.0000000000000864","article-title":"Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study","volume":"31","author":"Petrioli","year":"2020","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ccell.2022.12.008_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nature23306","article-title":"Integrative clinical genomics of metastatic cancer","volume":"548","author":"Robinson","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance","volume":"5","author":"Zou","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1083\/jcb.134.2.529","article-title":"Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2","volume":"134","author":"Maher","year":"1996","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ccell.2022.12.008_bib43","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T\u00a0cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib44","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1172\/JCI120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2022.12.008_bib45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jid.2018.12.024","article-title":"BET inhibition modifies melanoma infiltrating T\u00a0cells and enhances response to PD-L1 blockade","volume":"139","author":"Nikbakht","year":"2019","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ccell.2022.12.008_bib46","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/2326-6066.CIR-16-0060","article-title":"Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T\u00a0cells","volume":"4","author":"Homet Moreno","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.molcel.2012.11.022","article-title":"Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer","volume":"49","author":"Chocarro-Calvo","year":"2013","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib48","doi-asserted-by":"crossref","first-page":"25562","DOI":"10.1074\/jbc.M201196200","article-title":"Acetylation of beta-catenin by CREB-binding protein (CBP)","volume":"277","author":"Wolf","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ccell.2022.12.008_bib49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/emmm.201201606","article-title":"SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating beta-catenin","volume":"5","author":"Simic","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/1535-7163.MCT-12-0930","article-title":"Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents","volume":"12","author":"Yang","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ccell.2022.12.008_bib51","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/onc.2008.436","article-title":"Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect","volume":"28","author":"Lara","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2022.12.008_bib52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","article-title":"NAD+ and sirtuins in aging and disease","volume":"24","author":"Imai","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ccell.2022.12.008_bib53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41556-021-00672-3","article-title":"LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy","volume":"23","author":"Li","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2022.12.008_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ccell.2022.12.008_bib55","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1211485","article-title":"Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses","volume":"334","author":"Anastasiou","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.12.008_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature10598","article-title":"Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation","volume":"480","author":"Yang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib57","doi-asserted-by":"crossref","first-page":"ra73","DOI":"10.1126\/scisignal.2000431","article-title":"Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth","volume":"2","author":"Hitosugi","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ccell.2022.12.008_bib58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Anastasiou","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ccell.2022.12.008_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2326-6066.CIR-16-0019","article-title":"Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade","volume":"5","author":"Nathanson","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib60","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.12.008_bib62","first-page":"46","article-title":"PAK4 inhibition improves PD-1 blockade immunotherapy","volume":"1","author":"Abril-Rodriguez","year":"2020","journal-title":"Nat. Can."},{"key":"10.1016\/j.ccell.2022.12.008_bib63","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T\u00a0cells following PD-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T\u00a0cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib65","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/cancers13010048","article-title":"Hyper-progressive disease: the potential role and consequences of T-regulatory cells foiling anti-PD-1 cancer immunotherapy","volume":"13","author":"Tay","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ccell.2022.12.008_bib67","doi-asserted-by":"crossref","first-page":"e20182232","DOI":"10.1084\/jem.20182232","article-title":"PD-1 restraint of regulatory T\u00a0cell suppressive activity is critical for immune tolerance","volume":"218","author":"Tan","year":"2021","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody-fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib69","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/CAD.0000000000000837","article-title":"Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer","volume":"30","author":"Bosch-Barrera","year":"2019","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ccell.2022.12.008_bib70","article-title":"Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: a case report","volume":"99","author":"Fricke","year":"2020","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ccell.2022.12.008_bib71","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jtho.2019.08.007","article-title":"Characterization of hyperprogression after immunotherapy in a lung adenocarcinoma patient with strong expression of programmed death ligand 1","volume":"15","author":"Peng","year":"2020","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ccell.2022.12.008_bib72","first-page":"e3859","article-title":"Hyperprogression in pediatric melanoma metastatic to the breast treated with a checkpoint inhibitor","volume":"11","author":"Bernal Vaca","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.ccell.2022.12.008_bib73","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-020-02716-3","article-title":"Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma","volume":"70","author":"Schuiveling","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2022.12.008_bib74","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1078155219845436","article-title":"Hyperprogression after nivolumab for melanoma: a case report","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J.\u00a0Oncol. Pharm. Pract."},{"key":"10.1016\/j.ccell.2022.12.008_bib75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/cancers12030540","article-title":"MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma","volume":"12","author":"Forschner","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ccell.2022.12.008_bib76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/RLU.0000000000002849","article-title":"FDG PET findings of hyperprogression during immunotherapy in a patient with hepatocellular carcinoma","volume":"45","author":"Wang","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib77","doi-asserted-by":"crossref","first-page":"905S","DOI":"10.1177\/0145561320931215","article-title":"Metastatic renal cell carcinoma presenting as a rapidly enlarging endotracheal mass due to hyperprogression on anti-PD1 immunotherapy","volume":"100","author":"Hoshal","year":"2021","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.ccell.2022.12.008_bib78","article-title":"Hyperprogression of liver metastasis with neoadjuvant immunotherapy for soft tissue sarcoma","volume":"12","author":"Chan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.ccell.2022.12.008_bib79","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12885-019-5921-9","article-title":"Hyperprogression after immunotherapy in patients with malignant tumors of digestive system","volume":"19","author":"Ji","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib80","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.celrep.2014.03.026","article-title":"ARF and p53 coordinate tumor suppression of an oncogenic IFN-beta-STAT1-ISG15 signaling axis","volume":"7","author":"Forys","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2022.12.008_bib81","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib82","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","article-title":"TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma","volume":"160","author":"Oshimori","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.008_bib83","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","article-title":"Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion","volume":"572","author":"Paczulla","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib84","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature09161","article-title":"Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271","volume":"466","author":"Boiko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.008_bib85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2022.12.008_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2022.12.008_bib87","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2022.12.008_bib88","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1172\/JCI134402","article-title":"Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"J.\u00a0Clin. Invest."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610822005943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610822005943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:10:18Z","timestamp":1761523818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610822005943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1535610822005943"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2022.12.008","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2022.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}